• 8 December, 2017
  • The ISSCR joins the stem cell community in expressing sadness at the passing of Ihor Lemischka, PhD, Professor of Developmental and Regenerative Biology, Pharmacology and Systems Therapeutics at the Icahn School of Medicine.
    Full story
  • 6 December, 2017
  • The ISSCR celebrated its 15th year as a global voice for stem cell research, and our efforts and activities in 2017 reflect the key role the society plays in advancing the field. We advocated on behalf of members in the policy and regulatory arenas, provided resources for the public, and continued to provide a global forum for scientists to gather and share research.
    Full story
  • 17 November, 2017
  • The ISSCR commends the U.S. Food and Drug Administration (FDA) for reaffirming its regulatory authority over stem cell biologics and clarifying the criteria that determine which cell-based products fall under its oversight. These guidance documents will provide greater transparency for patients, medical professionals, and law enforcement authorities, about the legal status of stem cell treatments in the U.S.
    Full story
  • 4 October, 2017
  • A measure signed into law 3 October in the state of California, U.S., requires clinics to inform patients if they are using stem cell interventions that have not been approved by the Food and Drug Administration (FDA). ISSCR president Hans Clevers expresses support for the measure.
    Full story
  • ISSCR Opposes U.S. Restrictions on Fetal Tissue, Embryonic Stem Cell Research

  • 31 August, 2017
  • The ISSCR joined with more than 60 medical, patient, and academic groups in writing a letter to the U.S. Senate to oppose prohibitions or restrictions that would further impede the use of federal funding for fetal tissue or embryonic stem cell research.
    Full story
  • ISSCR Responds to FDA Announcement of Enforcement Direction for Stem Cell Treatments

  • 28 August, 2017
  • The ISSCR commends the U.S. Food and Drug Administration (FDA) for its policy direction and enforcement efforts, to provide “bright lines and appropriate oversight” for regulating stem cell treatments and regenerative medicine.
    Full story
  • ISSCR Congratulates Heather Rooke on New Role

  • 28 August, 2017
  • The ISSCR Scientific Director, Heather Rooke, has accepted a position at Harvard University, and will be leaving the ISSCR on 12 September.
    Full story
  • ISSCR Expresses Concern over FY2018 Budget Proposal in U.S.

  • 17 March, 2017
  • The FY2018 Discretionary Budget Plan put forward by the U.S. Administration includes dramatic cuts in funding for science and research programs that would threaten biomedical research and its translation into new therapies for millions of people worldwide.
    Full story
  • KayeMeier

    ISSCR Announces New Policy Director

  • 20 February, 2017
  • The ISSCR has named Kaye Meier to be its new Director of Policy. Meier is responsible for directing, planning, and executing policy and advocacy efforts, enabling the society and its members to actively engage in shaping stem cell-related public policy around the world.
    Full story
  • Board Letter to Stem Cell Community Regarding Travel to ISSCR 2017

  • 10 February, 2017
  • The ISSCR Board writes a letter to the stem cell community regarding travel to the ISSCR 2017 meeting, 14-17 June.
    Full story
  • The ISSCR Opposes U.S. Administration Executive Order on Immigration

  • 30 January, 2017
  • 1/30/2017 6:00:00 AM

    The ISSCR issued a statement opposing a U.S. executive order on immigration.
    Full story
  • The ISSCR Announces 2017 Award Recipients: McEwen Award for Innovation, ISSCR Dr. Susan Lim Outstanding Young Investigator Award, ISSCR Tobias Award Lecture, and ISSCR Public Service Award

  • 23 January, 2017
  • 1/23/2017 6:00:00 AM

    The ISSCR awards recognize outstanding scientists in the field of stem cell research and regenerative medicine. Award recipients are selected by their peers, and receive the honor at the ISSCR annual meeting, where they are invited to present their science.
    Full story
  • Message from the President: Sally Temple, PhD - 2016 Year in Review

  • 13 January, 2017
  • 2016 was an eventful year in stem cell science, with significant advances that furthered understanding of regenerative systems, human biology and disease modeling, and moved forward numerous programs in clinical translation.
    Full story
  • ISSCR Convenes Nucleus Forum to Support, Advance Biomedical Investment

  • 13 January, 2017
  • The ISSCR supports investment in biomedical research that advances the stem cell and regenerative medicine fields. To underscore this commitment, the ISSCR convenes meetings of leaders in industry, technology, healthcare, and private and public foundations to discuss how to advance biomedical research and investment.
    Full story
  • Human Fetal Tissue: A Critical Resource for Biomedical Research

  • 12 January, 2017
  • Fetal tissue research has made major contributions to our understanding of biology and the development of new medical technologies, including vaccines for many diseases that have saved millions of lives. The ISSCR is providing a portfolio of examples showing how the use of fetal tissue has led to therapies that have saved lives as well as ways in which fetal tissue research continues to be necessary for medical advances.
    Full story
  • ISSCR Opposes the REGROW Act

  • 15 September, 2016
  • The ISSCR opposes the REGROW Act, which would allow certain cell and tissue-based therapeutics to be marketed without first providing rigorous evidence of safety and efficacy. If passed, this legislation could negatively impact the development of stem cell therapies, the integrity of the emerging regenerative medicine market, and the health and safety of people using stem cell products approved under this Act.
    Full story
  • ISSCR Comments Before FDA Panel on Draft Guidances Relating to the Regulation of Human Cells, Tissues, or Cellular or Tissue-Based Products

  • 13 September, 2016
  • The ISSCR today underscored the need for careful oversight and regulation of stem cell research at every stage in the process of developing therapeutic products for patient use.
    Full story
  • ISSCR Comments Regarding Proposed Changes to the U.S. National Institutes of Health Guidelines on Human Stem Cell Research

  • 7 September, 2016
  • The ISSCR supports the continued assessment of the U.S. National Institutes of Health (NIH) Guidelines for Human Stem Cell Research. We applaud the proposed end to the current moratorium on U.S. federal funding of human-animal chimera research involving the introduction of human pluripotent cells into early stage animal embryos.
    Full story
  • ISSCR Congratulates George Q. Daley on Being Named Dean of Harvard Medical School

  • 10 August, 2016
  • ISSCR Congratulates George Q. Daley, ISSCR past president, for being named dean of Harvard Medical School. August, 2016.
    Full story
  • ISSCR Favors NIH Proposal on Human-Animal Chimera Research

  • 8 August, 2016
  • The ISSCR is pleased that the U.S. National Institutes of Health (NIH) is considering an end to the moratorium on NIH funding of human-animal chimera research (NIH Notice, 8-4-16).
    Full story
    View All ISSCR News